Xizhong Huang;David Dong Eun Chang;Jennifer Lorraine Gansert;Zhu Alexander Cao;Karl Maria Schumacher;Malte Peters
发明人:
Xizhong Huang,Malte Peters,Karl Maria Schumacher,Zhu Alexander Cao,Jennifer Lorraine Gansert,David Dong Eun Chang
申请号：
US13799076
公开号：
US08980259B2
申请日:
2013.03.13
申请国别(地区):
US
年份:
2015
代理人:
摘要：
The present invention relates to a pharmaceutical combination comprising an alpha-isoform specific phosphatidylinositol 3-kinase inhibitor compound, such as (S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide), or pharmaceutically acceptable salt thereof, and an insulin-like growth factor-1 receptor (IGF1R) inhibitor (e.g., the IGF1R inhibitor ANTIBODY A, or a variant or derivative thereof), a pharmaceutical composition comprising such combination, methods for treating cancer comprising administration of therapeutically effective amounts of such inhibitors to a subject in need thereof, and uses of such combination for the treatment of cancer.
